No Data
No Data
Piper Sandler Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $51
Scotiabank Initiates Coverage On Edgewise Therapeutics With Sector Outperform Rating, Announces Price Target of $50
Truist Financial Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating
Analysts Have Conflicting Sentiments on These Healthcare Companies: Edgewise Therapeutics (EWTX) and Walgreens Boots Alliance (WBA)
Leerink Partners Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Announces Target Price $50
Edgewise Therapeutics Analyst Ratings